Krystal Biotech (KRYS) Financials

$139.47 -22.82 (-14.06%)

Closing price 05/6/2025 04:00 PM Eastern

Extended Trading

$135.80 -3.67 (-2.63%)

As of 08:00 AM Eastern

Annual Income Statements for Krystal Biotech

This table shows Krystal Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-1.15	-7.92	-11	-19	-32	-70	-140	11	89
Consolidated Net Income / (Loss)	-1.15	-7.92	-11	-19	-32	-70	-140	11	89
Net Income / (Loss) Continuing Operations	-1.15	-7.92	-11	-19	-32	-70	-140	11	89
Total Pre-Tax Income	-1.15	-7.92	-11	-19	-32	-70	-140	13	95
Total Operating Income	-1.14	-4.77	-12	-22	-33	-68	-145	-110	66
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	0.00	48	270
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	51	291
Operating Revenue	-	-	-	-	-	0.00	0.00	51	291
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.09	20
Operating Cost of Revenue	-	-	-	-	-	0.00	-	3.09	20
Total Operating Expenses	1.14	4.77	12	22	33	68	145	157	205
Selling, General & Admin Expense	0.40	1.56	4.16	6.47	15	40	78	98	114
Research & Development Expense	0.74	3.21	7.76	16	18	28	42	46	54
Other Special Charges / (Income)	-	-	-	-	0.00	0.00	25	13	38
Total Other Income / (Expense), net	-0.01	-3.15	1.03	2.99	0.83	-1.30	5.22	123	30
Interest & Investment Income	-	-	-	-	-	0.20	5.22	23	30
Other Income / (Expense), net	-0.01	-3.15	1.03	-	0.83	0.00	0.00	100	0.00
Income Tax Expense	-	-	-	-	-	0.00	0.00	1.97	6.20
Basic Earnings per Share	($1.31)	($1.48)	($0.97)	($1.20)	($1.71)	($3.13)	($5.49)	$0.40	$3.12
Weighted Average Basic Shares Outstanding	877.49K	10.31M	11.20M	15.90M	18.79M	22.20M	25.49M	27.15M	28.59M
Diluted Earnings per Share	($1.31)	($1.48)	($0.97)	($1.20)	($1.71)	($3.13)	($5.49)	$0.39	$3.00
Weighted Average Diluted Shares Outstanding	877.49K	10.31M	11.20M	15.90M	18.79M	22.20M	25.49M	27.75M	29.74M
Weighted Average Basic & Diluted Shares Outstanding	877.49K	5.36M	11.20M	15.90M	18.79M	25.76M	-	28.29M	28.81M

This table shows Krystal Biotech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-30	-32	-45	-33	81	8.69	0.93	16	27	45
Consolidated Net Income / (Loss)	-30	-32	-45	-33	81	8.69	0.93	16	27	45
Net Income / (Loss) Continuing Operations	-30	-32	-45	-33	81	8.69	0.93	16	27	45
Total Pre-Tax Income	-30	-32	-45	-33	81	11	0.93	16	30	49
Total Operating Income	-31	-35	-49	-38	-26	3.14	-6.68	8.57	22	41
Total Gross Profit	0.00	-	0.00	0.00	8.56	39	43	64	77	86
Total Revenue	0.00	-	0.00	0.00	8.56	42	45	70	84	91
Operating Revenue	0.00	-	0.00	0.00	8.56	42	45	70	84	91
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	3.09	2.42	6.01	6.68	4.95
Operating Cost of Revenue	0.00	-	0.00	0.00	-	-	2.42	6.01	6.68	4.95
Total Operating Expenses	31	35	49	38	34	36	50	56	55	45
Selling, General & Admin Expense	20	24	24	26	24	25	26	28	29	31
Research & Development Expense	12	11	12	12	11	11	11	16	14	14
Total Other Income / (Expense), net	1.60	2.98	3.53	4.84	107	7.52	7.62	7.48	7.34	7.23
Other Income / (Expense), net	0.00	-	-	-	100	-	7.62	7.48	0.00	-15
Basic Earnings per Share	($1.17)	($1.23)	($1.76)	($1.25)	$2.88	$0.53	$0.03	$0.54	$0.95	$1.60
Weighted Average Basic Shares Outstanding	25.62M	25.49M	25.71M	26.66M	28.04M	27.15M	28.30M	28.60M	28.72M	28.59M
Diluted Earnings per Share	($1.17)	($1.23)	($1.76)	($1.25)	$2.79	$0.61	$0.03	$0.53	$0.91	$1.53
Weighted Average Diluted Shares Outstanding	25.62M	25.49M	25.71M	26.66M	28.89M	27.75M	29.29M	29.64M	29.90M	29.74M
Weighted Average Basic & Diluted Shares Outstanding	25.75M	0.00	27.99M	-	28.21M	28.29M	28.56M	28.73M	28.76M	28.81M

This table details how cash moves in and out of Krystal Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	1.92	48	54	84	81	73	-179	196	-13
Net Cash From Operating Activities	-1.31	-3.89	-9.45	-19	-26	-48	-101	-89	123
Net Cash From Continuing Operating Activities	-1.31	-3.89	-9.45	-19	-26	-48	-101	-89	123
Net Income / (Loss) Continuing Operations	-1.15	-7.92	-11	-19	-32	-70	-140	11	89
Consolidated Net Income / (Loss)	-1.15	-7.92	-11	-19	-32	-70	-140	11	89
Depreciation Expense	0.00	0.02	0.14	1.09	1.85	1.85	2.64	5.01	5.97
Amortization Expense	-	-	-	-	-	0.92	0.74	-1.28	0.75
Non-Cash Adjustments To Reconcile Net Income	0.04	3.51	0.79	1.31	3.31	17	33	-65	73
Changes in Operating Assets and Liabilities, net	-0.20	0.50	0.51	-2.00	0.93	2.05	2.66	-38	-45
Net Cash From Investing Activities	-0.02	-0.21	-10	-4.99	-11	-227	-114	83	-163
Net Cash From Continuing Investing Activities	-0.02	-0.21	-10	-4.99	-11	-227	-114	83	-163
Purchase of Property, Plant & Equipment	-0.02	-0.21	-2.23	-6.40	-15	-68	-53	-12	-4.24
Purchase of Investments	-	-	-8.09	-9.09	-3.21	-190	-319	-509	-458
Divestitures	-	-	-	-	-	0.00	0.00	100	0.00
Sale and/or Maturity of Investments	-	-	-	11	6.87	32	258	503	299
Net Cash From Financing Activities	3.25	52	74	108	118	348	35	203	27
Net Cash From Continuing Financing Activities	3.25	52	74	108	118	348	35	203	27
Issuance of Common Equity	0.10	42	74	108	118	356	29	160	0.00
Other Financing Activities, net	-	-	-	-	0.00	-7.96	6.36	43	27
Effect of Exchange Rate Changes	-	-	-	-	0.00	0.00	-0.04	-0.16	-0.46
Cash Income Taxes Paid	-	-	-	-	-	-	0.00	0.00	5.67

This table details how cash moves in and out of Krystal Biotech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-32	-25	-21	135	97	-15	0.68	-13	28	-29
Net Cash From Operating Activities	-20	-22	-26	-34	-21	-7.23	16	-4.17	59	53
Net Cash From Continuing Operating Activities	-20	-23	-26	-34	-21	-7.23	16	-4.17	59	53
Net Income / (Loss) Continuing Operations	-30	-32	-45	-33	81	8.69	0.93	16	27	45
Consolidated Net Income / (Loss)	-30	-32	-45	-33	81	8.69	0.93	16	27	45
Depreciation Expense	0.98	-0.32	1.09	1.26	1.14	1.52	1.43	1.84	1.34	1.36
Amortization Expense	-	-	0.22	0.22	0.23	-1.95	0.18	0.19	0.19	0.19
Non-Cash Adjustments To Reconcile Net Income	8.84	9.24	22	-3.19	-94	10	20	24	18	12
Changes in Operating Assets and Liabilities, net	0.33	-0.58	-3.69	0.73	-9.62	-26	-6.44	-45	13	-5.73
Net Cash From Investing Activities	-15	-5.21	3.56	-16	105	-10	-26	-19	-34	-84
Net Cash From Continuing Investing Activities	-15	-5.21	3.56	-16	105	-10	-26	-19	-34	-84
Purchase of Property, Plant & Equipment	-14	-5.22	-5.38	-2.79	-1.78	-1.85	-1.26	-1.13	-1.05	-0.80
Purchase of Investments	-67	-104	-146	-174	-106	-83	-88	-113	-113	-143
Sale and/or Maturity of Investments	67	104	155	161	113	75	64	95	79	60
Net Cash From Financing Activities	2.12	3.07	1.47	185	13	2.62	11	11	3.37	2.43
Net Cash From Continuing Financing Activities	2.12	3.07	1.47	185	13	2.62	11	11	3.37	2.43
Other Financing Activities, net	-	7.01	1.47	25	14	2.61	11	11	3.37	2.43
Effect of Exchange Rate Changes	-	-0.04	-	-	0.01	-0.14	0.19	-0.34	0.29	-0.59
Cash Income Taxes Paid	-	-	-	-	-	-	-	-	3.15	0.52

This table presents Krystal Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2022	12/31/2022	12/31/2023	12/31/2024
Total Assets	2.18	50	116	209	311	558	558	818	1,056
Total Current Assets	2.17	50	113	196	275	384	384	588	742
Cash & Equivalents	1.92	50	104	188	268	162	162	358	345
Short-Term Investments	-	0.00	8.09	6.17	2.99	217	217	174	253
Accounts Receivable	-	-	-	-	-	-	0.00	42	105
Inventories, net	-	-	-	-	-	-	0.00	6.99	27
Prepaid Expenses	0.25	0.32	0.89	2.20	3.80	4.61	4.61	6.71	13
Plant, Property, & Equipment, net	0.01	0.20	3.01	8.48	31	162	162	161	155
Total Noncurrent Assets	0.00	0.00	0.45	4.67	4.91	13	13	69	159
Long-Term Investments	-	-	-	0.50	0.00	4.62	4.62	62	152
Other Noncurrent Operating Assets	-	-	0.45	4.17	4.91	8.37	8.37	7.29	6.51
Total Liabilities & Shareholders' Equity	2.18	50	116	209	311	558	558	818	1,056
Total Liabilities	1.89	0.64	2.89	6.11	19	36	36	40	109
Total Current Liabilities	0.04	0.64	2.60	3.33	15	29	29	33	102
Accounts Payable	0.04	0.64	2.60	1.02	2.11	27	27	26	64
Accrued Expenses	-	-	-	1.83	5.11	-	-	5.98	37
Other Current Liabilities	-	-	-	0.48	8.24	1.56	1.56	1.47	1.22
Total Noncurrent Liabilities	1.85	0.00	0.29	2.78	3.31	7.37	7.37	6.62	7.46
Other Noncurrent Operating Liabilities	-	0.00	0.29	2.78	3.31	7.37	7.37	6.62	7.46
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	0.29	49	113	203	292	522	522	779	946
Total Preferred & Common Equity	0.29	49	113	203	292	522	522	779	946
Total Common Equity	-1.12	49	113	203	292	522	522	779	946
Common Stock	0.03	59	133	242	363	804	804	1,048	1,127
Retained Earnings	-1.15	-9.07	-20	-39	-71	-281	-281	-270	-181
Accumulated Other Comprehensive Income / (Loss)	-	0.00	0.00	0.01	0.01	-0.73	-0.73	0.64	-0.19

This table presents Krystal Biotech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	12/31/2022	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	558	684	790	853	918	982
Total Current Assets	384	484	582	602	683	713
Cash & Equivalents	162	276	373	359	346	374
Short-Term Investments	217	202	189	179	214	214
Accounts Receivable	-	-	9.32	46	103	97
Inventories, net	-	-	5.28	11	12	19
Prepaid Expenses	4.61	6.49	5.47	6.49	7.75	8.96
Plant, Property, & Equipment, net	162	164	164	160	159	157
Total Noncurrent Assets	13	36	44	91	76	113
Long-Term Investments	4.62	28	37	84	69	106
Other Noncurrent Operating Assets	8.37	7.88	7.65	7.04	6.79	6.67
Total Liabilities & Shareholders' Equity	558	684	790	853	918	982
Total Liabilities	36	31	34	54	79	96
Total Current Liabilities	29	24	28	48	72	90
Accounts Payable	27	22	26	35	49	59
Accrued Expenses	-	-	-	11	22	30
Other Current Liabilities	1.56	1.53	1.50	1.43	1.36	1.29
Total Noncurrent Liabilities	7.37	7.01	6.82	6.47	6.91	6.95
Other Noncurrent Operating Liabilities	7.37	7.01	6.82	6.47	6.91	6.95
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	522	653	756	799	839	886
Total Preferred & Common Equity	522	653	756	799	839	886
Total Common Equity	522	653	756	799	839	886
Common Stock	804	1,013	1,035	1,068	1,093	1,110
Retained Earnings	-281	-359	-279	-269	-253	-226
Accumulated Other Comprehensive Income / (Loss)	-0.73	-0.24	-0.38	-0.30	-0.63	1.51

This table displays calculated financial ratios and metrics derived from Krystal Biotech's official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	473.02%
EBITDA Growth	0.00%	-587.89%	-36.10%	-95.30%	-44.42%	-116.08%	-116.49%	95.77%	1,307.02%
EBIT Growth	0.00%	-588.70%	-37.49%	-102.78%	-45.68%	-112.25%	-112.66%	93.30%	775.39%
NOPAT Growth	0.00%	-317.50%	-149.71%	-85.31%	-49.45%	-106.90%	-112.66%	8.49%	166.04%
Net Income Growth	0.00%	-588.70%	-37.49%	-75.30%	-68.52%	-116.28%	-101.20%	107.81%	715.58%
EPS Growth	0.00%	-12.98%	34.46%	-23.71%	-42.50%	-83.04%	-75.40%	107.10%	669.23%
Operating Cash Flow Growth	0.00%	-196.72%	-142.80%	-97.88%	-39.56%	-83.79%	-109.79%	11.70%	238.98%
Free Cash Flow Firm Growth	0.00%	0.00%	-229.96%	-129.00%	-54.86%	-370.06%	38.55%	-36.84%	135.37%
Invested Capital Growth	0.00%	-154.17%	1,352.14%	496.04%	138.46%	564.87%	0.00%	33.28%	6.63%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	492.55%	20.29%
EBITDA Q/Q Growth	0.00%	0.00%	-26.73%	-8.59%	-12.13%	-20.54%	-9.53%	95.85%	124.97%
EBIT Q/Q Growth	0.00%	0.00%	-26.99%	-9.62%	-11.94%	-20.17%	-9.75%	93.41%	139.31%
NOPAT Q/Q Growth	0.00%	0.00%	-29.56%	-9.62%	-14.84%	-20.17%	-9.75%	10.00%	123.76%
Net Income Q/Q Growth	0.00%	0.00%	-26.99%	-9.46%	-18.52%	-19.65%	-7.90%	136.67%	70.24%
EPS Q/Q Growth	0.00%	0.00%	-76.36%	-0.84%	-17.12%	-15.07%	-5.37%	126.90%	44.23%
Operating Cash Flow Q/Q Growth	0.00%	-48.25%	-17.27%	-22.90%	-4.09%	-36.72%	-1.44%	14.53%	94.84%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-22.56%	-13.40%	-135.21%	45.10%	-13.78%	817.93%
Invested Capital Q/Q Growth	0.00%	0.00%	73,350.00%	96.76%	35.60%	201.56%	0.00%	17.27%	2.67%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	93.90%	93.09%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-11.83%	24.92%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-216.43%	22.61%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-19.19%	22.61%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	21.56%	30.69%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	84.76%	93.50%
Interest Burden Percent	100.00%	100.00%	100.00%	86.45%	100.00%	101.90%	96.40%	-132.59%	145.15%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	15.24%	6.50%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-57.60%	32.22%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-78.86%	28.09%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	59.28%	-21.89%
Return on Equity (ROE)	-397.92%	-31.83%	-13.39%	-12.08%	-13.00%	-17.09%	-26.80%	1.68%	10.34%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-677.35%	-445.69%	-238.14%	-207.72%	-73.42%	-86.13%	25.80%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.41%	7.01%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.59%	9.51%
Return on Common Equity (ROCE)	1,538.00%	-30.93%	-13.39%	-12.08%	-13.00%	-17.09%	-26.80%	1.68%	10.34%
Return on Equity Simple (ROE_SIMPLE)	-397.92%	-16.01%	-9.62%	-9.41%	-11.01%	-13.32%	-26.80%	1.40%	9.42%
Net Operating Profit after Tax (NOPAT)	-0.80	-3.34	-8.34	-15	-23	-48	-102	-93	61
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-183.45%	21.14%
Net Nonoperating Expense Percent (NNEP)	-479.32%	-18.44%	-3.16%	-2.37%	-3.90%	-6.65%	-9.99%	21.26%	4.13%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-19.46%	-11.95%	6.49%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	6.10%	6.91%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	194.09%	39.13%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	91.58%	18.44%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	310.33%	70.48%
Earnings before Interest and Taxes (EBIT)	-1.15	-7.92	-11	-22	-32	-68	-145	-9.73	66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.15	-7.90	-11	-21	-30	-66	-142	-6.00	72
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.18	2.65	4.72	4.05	2.98	3.91	4.49	4.76
Price to Tangible Book Value (P/TBV)	0.00	2.18	2.65	4.72	4.05	2.98	3.91	4.49	4.76
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	69.02	15.51
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	320.09	50.53
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.31%	1.98%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	128.38	87.54	43.76	8.46	11.96	15.75	19.09
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	57.30	12.93
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	51.87
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	57.17
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	61.15
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	30.43
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	76.36
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	6.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	6.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.25	-1.00	-0.99	-0.97	-0.94	-0.80	-0.73	-0.75	-0.78
Leverage Ratio	7.55	1.05	1.02	1.03	1.05	1.07	1.07	1.06	1.09
Compound Leverage Factor	7.55	1.05	1.02	0.89	1.05	1.09	1.03	-1.40	1.58
Debt to Total Capital	86.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	86.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	65.95%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-52.39%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-1.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.07	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-1.61	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-2.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-2.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	101.37	62.84	94.64	38.16	25.42	32.99	53.24	25.67
Noncontrolling Interest Sharing Ratio	486.51%	2.83%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	50.44	77.99	43.39	58.88	17.80	13.30	13.30	17.76	7.28
Quick Ratio	44.72	77.49	43.05	58.22	17.56	13.14	13.14	17.35	6.89
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-3.01	-9.92	-23	-35	-165	-102	-139	49
Operating Cash Flow to CapEx	-8,740.00%	-1,852.38%	-422.78%	-292.08%	-175.73%	-70.15%	-189.83%	-752.64%	2,912.22%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	-110.86	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	-32.13	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-77.93	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.31
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.96
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.20
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.31	1.84
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.12	0.45
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	92.21
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	304.69
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3,122.02	815.27
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3,122.02	-418.36
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.22	-0.12	1.47	8.73	21	138	138	185	197
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.31	1.52
Increase / (Decrease) in Invested Capital	0.00	-0.33	1.58	7.27	12	118	0.00	46	12
Enterprise Value (EV)	0.00	58	188	764	911	1,172	1,656	2,905	3,756
Market Capitalization	0.00	108	300	959	1,182	1,556	2,040	3,499	4,506
Book Value per Share	($1.27)	$4.83	$7.85	$11.72	$14.82	$23.48	$20.28	$27.61	$32.91
Tangible Book Value per Share	($1.27)	$4.83	$7.85	$11.72	$14.82	$23.48	$20.28	$27.61	$32.91
Total Capital	2.13	49	113	203	292	522	522	779	946
Total Debt	1.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	1.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-0.08	-50	-112	-194	-271	-384	-384	-594	-750
Capital Expenditures (CapEx)	0.02	0.21	2.23	6.40	15	68	53	12	4.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.20	-0.32	-1.71	-1.13	-12	-24	-24	23	43
Debt-free Net Working Capital (DFNWC)	2.13	49	110	193	260	355	355	555	640
Net Working Capital (NWC)	2.13	49	110	193	260	355	355	555	640
Net Nonoperating Expense (NNE)	0.35	4.58	2.55	3.63	9.07	22	38	-104	-28
Net Nonoperating Obligations (NNO)	-0.07	-50	-112	-194	-271	-384	-384	-594	-750
Total Depreciation and Amortization (D&A)	0.00	0.02	0.14	1.09	1.85	2.77	3.39	3.73	6.71
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	44.65%	14.64%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,094.33%	220.32%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,094.33%	220.32%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.31)	($1.48)	($0.97)	($1.20)	($1.71)	$0.00	$0.00	$0.40	$3.12
Adjusted Weighted Average Basic Shares Outstanding	877.49K	10.31M	11.20M	17.36M	22.19M	0.00	0.00	27.15M	28.59M
Adjusted Diluted Earnings per Share	($1.31)	($1.48)	($0.97)	($1.20)	($1.71)	$0.00	$0.00	$0.39	$3.00
Adjusted Weighted Average Diluted Shares Outstanding	877.49K	10.31M	11.20M	17.36M	22.19M	0.00	0.00	27.75M	29.74M
Adjusted Basic & Diluted Earnings per Share	($1.31)	($1.48)	($0.97)	($1.20)	($1.71)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	877.49K	5.36M	11.20M	15.90M	18.79M	0.00	0.00	28.29M	28.81M
Normalized Net Operating Profit after Tax (NOPAT)	-0.80	-3.34	-8.34	-15	-23	-48	-84	-82	96
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-162.55%	33.21%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	25.44%	32.82%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-45.76	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-32.03	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-91.56	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-77.83	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Krystal Biotech's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	879.91%	116.26%
EBITDA Growth	-104.96%	-59.42%	3.44%	-34.79%	347.32%	107.73%	105.35%	149.40%	-68.21%	926.93%
EBIT Growth	-100.94%	-58.93%	2.79%	-35.36%	335.31%	109.02%	101.91%	142.17%	-69.69%	737.90%
NOPAT Growth	-100.94%	-58.93%	2.79%	-32.33%	-18.07%	112.89%	80.44%	131.21%	178.80%	1,219.09%
Net Income Growth	-91.48%	-46.99%	9.34%	-18.15%	370.51%	127.12%	102.06%	146.88%	-66.34%	423.23%
EPS Growth	-67.14%	-29.47%	11.56%	-13.64%	338.46%	149.59%	101.70%	142.40%	-67.38%	150.82%
Operating Cash Flow Growth	-171.37%	-6.84%	-68.82%	20.60%	-7.81%	67.61%	160.74%	87.81%	377.29%	830.68%
Free Cash Flow Firm Growth	-175.96%	81.69%	-13.87%	184.42%	60.82%	-76.40%	63.80%	-314.37%	69.21%	167.87%
Invested Capital Growth	201.56%	0.00%	82.65%	0.00%	13.65%	33.28%	20.25%	0.00%	21.80%	6.63%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	392.55%	7.37%	55.32%	19.29%	8.71%
EBITDA Q/Q Growth	-12.32%	-15.15%	-35.39%	23.03%	306.10%	-96.40%	-54.42%	610.98%	32.64%	16.18%
EBIT Q/Q Growth	-11.89%	-10.55%	-40.42%	22.07%	294.51%	-95.76%	-70.29%	1,621.57%	39.81%	17.17%
NOPAT Q/Q Growth	-9.38%	-10.55%	-40.42%	22.07%	2.41%	112.07%	-313.07%	224.35%	146.43%	102.03%
Net Income Q/Q Growth	-6.20%	-7.38%	-41.32%	26.68%	343.14%	-89.24%	-89.28%	1,570.39%	74.59%	67.33%
EPS Q/Q Growth	-6.36%	-5.13%	-43.09%	28.98%	323.20%	-78.14%	-95.08%	1,666.67%	71.70%	68.13%
Operating Cash Flow Q/Q Growth	54.28%	-13.41%	-17.14%	-30.72%	37.92%	65.93%	319.69%	-126.23%	1,512.12%	-10.22%
Free Cash Flow Firm Q/Q Growth	-2.79%	78.75%	-314.07%	193.35%	-147.71%	4.35%	15.02%	-452.78%	93.15%	310.84%
Invested Capital Q/Q Growth	14.68%	0.00%	6.32%	-100.00%	0.00%	17.27%	-4.08%	18.65%	-8.74%	2.67%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	100.00%	92.66%	94.65%	91.45%	92.03%	94.57%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	880.93%	6.43%	5.62%	25.70%	28.58%	30.55%
Operating Margin	0.00%	0.00%	0.00%	0.00%	-303.80%	7.44%	-14.77%	12.19%	26.76%	45.40%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	864.97%	7.44%	2.06%	22.83%	26.76%	28.84%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	943.75%	20.63%	2.06%	22.15%	32.42%	49.90%
Tax Burden Percent	100.00%	100.81%	100.00%	100.00%	100.00%	81.56%	100.00%	97.03%	91.30%	93.56%
Interest Burden Percent	94.91%	91.44%	92.78%	87.28%	109.11%	339.72%	100.00%	100.00%	132.70%	184.93%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.97%	8.70%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	-17.58%	2.34%	-8.74%	18.72%	33.82%	69.19%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	-39.31%	1.20%	-10.09%	16.41%	32.78%	68.58%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	30.21%	-0.90%	7.84%	-12.31%	-25.81%	-53.42%
Return on Equity (ROE)	-27.88%	-26.80%	-22.52%	0.00%	12.63%	1.43%	-0.90%	6.42%	8.00%	15.77%
Cash Return on Invested Capital (CROIC)	-200.87%	-73.42%	-146.87%	0.00%	-82.66%	-86.13%	-60.08%	-219.98%	-3.93%	25.80%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	10.97%	0.55%	0.26%	4.14%	7.29%	8.94%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	11.97%	1.52%	0.26%	4.01%	8.83%	15.47%
Return on Common Equity (ROCE)	-27.88%	-26.80%	-22.52%	0.00%	12.63%	1.43%	-0.90%	6.42%	8.00%	15.77%
Return on Equity Simple (ROE_SIMPLE)	-24.84%	0.00%	-20.72%	0.00%	-3.94%	0.00%	7.15%	12.63%	5.91%	0.00%
Net Operating Profit after Tax (NOPAT)	-22	-24	-34	-27	-26	3.14	-6.68	8.31	20	41
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	-303.80%	7.44%	-14.77%	11.83%	24.43%	45.40%
Net Nonoperating Expense Percent (NNEP)	-2.10%	-2.01%	-2.28%	0.00%	21.73%	1.14%	1.35%	2.31%	1.04%	0.61%
Return On Investment Capital (ROIC_SIMPLE)	-	-4.66%	-	-	-	0.40%	-	-	-	4.37%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	7.34%	5.35%	8.55%	7.97%	5.43%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	276.96%	58.76%	57.59%	39.31%	34.25%	34.33%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	124.23%	26.98%	24.21%	22.17%	16.12%	14.84%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	401.19%	85.74%	109.43%	79.26%	65.27%	49.17%
Earnings before Interest and Taxes (EBIT)	-31	-35	-49	-38	74	3.14	0.93	16	22	26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-30	-35	-48	-37	75	2.71	2.54	18	24	28
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.43	3.91	3.16	0.00	4.30	4.49	6.28	6.25	5.90	4.76
Price to Tangible Book Value (P/TBV)	3.43	3.91	3.16	0.00	4.30	4.49	6.28	6.25	5.90	4.76
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	379.54	69.02	52.31	31.55	21.65	15.51
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	320.09	87.80	49.50	99.86	50.53
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.31%	1.14%	2.02%	1.00%	1.98%
Enterprise Value to Invested Capital (EV/IC)	10.15	11.96	10.58	0.00	16.84	15.75	24.84	21.98	23.67	19.09
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	309.57	57.30	45.82	27.77	18.78	12.93
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	140.92	51.87
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	165.22	57.17
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	165.22	61.15
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	71.60	30.43
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	76.36
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.80	-0.73	-0.81	0.00	-0.77	-0.75	-0.78	-0.75	-0.79	-0.78
Leverage Ratio	1.09	1.07	1.08	0.00	1.06	1.06	1.06	1.09	1.08	1.09
Compound Leverage Factor	1.03	0.98	1.00	0.00	1.15	3.60	1.06	1.09	1.43	2.01
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	29.51	33.64	39.87	0.00	57.30	53.29	56.16	40.60	33.29	25.54
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	13.30	13.30	20.25	0.00	21.10	17.76	12.66	9.50	7.97	7.28
Quick Ratio	13.14	13.14	19.98	0.00	20.72	17.35	12.29	9.23	7.66	6.89
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-115	-24	-101	94	-45	-43	-36	-202	-14	29
Operating Cash Flow to CapEx	-140.07%	-428.00%	-486.08%	-1,225.45%	-1,191.80%	-391.55%	1,260.95%	-368.52%	5,626.86%	6,597.13%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.01	0.07	0.12	0.18	0.27	0.31
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.61	4.53	3.96
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.95	1.53	1.20
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.05	0.31	0.59	1.05	1.51	1.84
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.12	0.19	0.24	0.43	0.45
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	226.68	80.56	92.21
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	385.81	239.17	304.69
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	3,122.02	1,894.82	1,544.55	849.77	815.27
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	-3,122.02	-1,894.82	-932.06	-530.04	-418.36
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	138	138	147	0.00	157	185	177	210	192	197
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.06	0.31	0.59	1.58	1.38	1.52
Increase / (Decrease) in Invested Capital	93	0.00	67	-121	19	46	30	210	34	12
Enterprise Value (EV)	1,405	1,656	1,557	0.00	2,649	2,905	4,396	4,616	4,536	3,756
Market Capitalization	1,789	2,040	2,063	3,029	3,247	3,499	5,019	5,244	5,230	4,506
Book Value per Share	$20.35	$20.28	$25.35	$0.00	$27.00	$27.61	$28.25	$29.37	$30.83	$32.91
Tangible Book Value per Share	$20.35	$20.28	$25.35	$0.00	$27.00	$27.61	$28.25	$29.37	$30.83	$32.91
Total Capital	522	522	653	0.00	756	779	799	839	886	946
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-384	-384	-506	0.00	-599	-594	-622	-629	-694	-750
Capital Expenditures (CapEx)	14	5.22	5.38	2.79	1.78	1.85	1.26	1.13	1.05	0.80
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-24	-24	-17	0.00	-7.52	23	16	51	35	43
Debt-free Net Working Capital (DFNWC)	355	355	460	0.00	555	555	555	611	624	640
Net Working Capital (NWC)	355	355	460	0.00	555	555	555	611	624	640
Net Nonoperating Expense (NNE)	7.83	7.71	11	6.58	-107	-5.56	-7.62	-7.26	-6.70	-4.10
Net Nonoperating Obligations (NNO)	-384	-384	-506	0.00	-599	-594	-622	-629	-694	-750
Total Depreciation and Amortization (D&A)	0.98	-0.32	1.31	1.48	1.37	-0.43	1.61	2.02	1.53	1.56
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	-87.94%	44.65%	17.09%	30.87%	14.62%	14.64%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	6,481.36%	1,094.33%	578.08%	367.51%	258.22%	220.32%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	6,481.36%	1,094.33%	578.08%	367.51%	258.22%	220.32%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.17)	($1.23)	$0.00	$0.00	$2.88	$0.53	$0.03	$0.54	$0.95	$1.60
Adjusted Weighted Average Basic Shares Outstanding	25.62M	25.49M	0.00	0.00	28.04M	27.15M	28.30M	28.60M	28.72M	28.59M
Adjusted Diluted Earnings per Share	($1.17)	($1.23)	$0.00	$0.00	$2.79	$0.61	$0.03	$0.53	$0.91	$1.53
Adjusted Weighted Average Diluted Shares Outstanding	25.62M	25.49M	0.00	0.00	28.89M	27.75M	29.29M	29.64M	29.90M	29.74M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	25.75M	0.00	0.00	0.00	28.21M	28.29M	28.56M	28.73M	28.76M	28.81M
Normalized Net Operating Profit after Tax (NOPAT)	-22	-24	-25	-27	-18	2.20	4.07	20	32	29
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	-212.66%	5.21%	9.00%	29.08%	38.04%	31.78%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	943.75%	25.29%	2.06%	22.83%	35.51%	53.34%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Krystal Biotech's Financials

When does Krystal Biotech's financial year end?

According to the most recent income statement we have on file, Krystal Biotech's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Krystal Biotech's net income changed over the last 8 years?

Krystal Biotech's net income appears to be on a downward trend, with a most recent value of $89.16 million in 2024, falling from -$1.15 million in 2016. The previous period was $10.93 million in 2023. See where experts think Krystal Biotech is headed by visiting Krystal Biotech's forecast page.

What is Krystal Biotech's operating income?

Krystal Biotech's total operating income in 2024 was $65.70 million, based on the following breakdown:

Total Gross Profit: $270.45 million
Total Operating Expenses: $204.76 million

How has Krystal Biotech revenue changed over the last 8 years?

Over the last 8 years, Krystal Biotech's total revenue changed from $0.00 in 2016 to $290.52 million in 2024, a change of 29,051,500,000.0%.

How much debt does Krystal Biotech have?

Krystal Biotech's total liabilities were at $109.46 million at the end of 2024, a 175.6% increase from 2023, and a 5,682.3% increase since 2016.

How much cash does Krystal Biotech have?

In the past 8 years, Krystal Biotech's cash and equivalents has ranged from $1.92 million in 2016 to $358.33 million in 2023, and is currently $344.87 million as of their latest financial filing in 2024.

How has Krystal Biotech's book value per share changed over the last 8 years?

Over the last 8 years, Krystal Biotech's book value per share changed from -1.27 in 2016 to 32.91 in 2024, a change of -2,685.1%.

Related Companies

This page (NASDAQ:KRYS) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Krystal Biotech (KRYS) Financials

Frequently Asked Questions About Krystal Biotech's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Krystal Biotech (KRYS) Financials

Annual Income Statements for Krystal Biotech

Quarterly Income Statements for Krystal Biotech

Annual Cash Flow Statements for Krystal Biotech

Quarterly Cash Flow Statements for Krystal Biotech

Annual Balance Sheets for Krystal Biotech

Quarterly Balance Sheets for Krystal Biotech

Annual Metrics and Ratios for Krystal Biotech

Quarterly Metrics and Ratios for Krystal Biotech

Frequently Asked Questions About Krystal Biotech's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools